Literature DB >> 20549488

The effects of d-amphetamine, methylphenidate, sydnocarb, and caffeine on prepulse inhibition of the startle reflex in DBA/2 mice.

Dorothy G Flood1, Eva Zuvich, Michael J Marino, Maciej Gasior.   

Abstract

RATIONALE: Dopamine (DA) agonists decrease prepulse inhibition (PPI) and are widely used in translational models for the sensorimotor gating deficits in schizophrenia. Reductions in PPI induced by DA agonists are routinely reversed by antipsychotics in these translational models. Nevertheless, under conditions of low-baseline PPI, DA agonists may increase PPI in humans and experimental animals. DBA/2 mice have naturally low-baseline PPI, which as in the drug-induced translational models, is increased by antipsychotics.
OBJECTIVE: Determine whether DBA/2 mice respond like other models of low-baseline PPI by evaluating the effect of psychostimulants (caffeine, 30-100 mg/kg IP) and the indirect DA agonists d-amphetamine (0.3-10 mg/kg IP), methylphenidate (10-100 mg/kg IP), and sydnocarb (10-30 mg/kg IP), a selective DA transporter inhibitor on PPI. Furthermore, baseline PPI in DBA/2 mice was increased by noise exposure and the effect of d-amphetamine was assessed.
RESULTS: PPI was increased at one dose for each of the psychostimulants when baseline PPI was low in naïve DBA/2 mice. Effective doses were 3 mg/kg of d-amphetamine, 30 mg/kg of methylphenidate, 30 mg/kg of sydnocarb, and 100 mg/kg of caffeine. Higher doses of d-amphetamine (10 mg/kg) and methylphenidate (100 mg/kg IP) decreased PPI. When the baseline PPI was increased by noise exposure, 10 mg/kg of d-amphetamine only reduced PPI.
CONCLUSION: Lower doses of psychostimulants increased PPI in naïve DBA/2 mice in a manner consistent with their naturally low-baseline PPI, and higher doses decreased PPI, consistent with effects observed in most mouse strains.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20549488     DOI: 10.1007/s00213-010-1901-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  43 in total

1.  Effects of selective dopamine D1-like and D2-like agonists on prepulse inhibition of startle in inbred C3H/HeJ, SPRET/EiJ, and CAST/EiJ mice.

Authors:  Rebecca J Ralph; S Barak Caine
Journal:  Psychopharmacology (Berl)       Date:  2006-09-22       Impact factor: 4.530

2.  Exposure to an augmented acoustic environment alters auditory function in hearing-impaired DBA/2J mice.

Authors:  J G Turner; J F Willott
Journal:  Hear Res       Date:  1998-04       Impact factor: 3.208

3.  Comparison of apomorphine, amphetamine and dizocilpine disruptions of prepulse inhibition in inbred and outbred mice strains.

Authors:  G B Varty; N Walters; M Cohen-Williams; G J Carey
Journal:  Eur J Pharmacol       Date:  2001-07-13       Impact factor: 4.432

4.  Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies.

Authors:  Neal R Swerdlow; Angela Eastvold; Blythe Karban; Yvonne Ploum; Nora Stephany; Mark A Geyer; Kristin Cadenhead; Pamela P Auerbach
Journal:  Psychopharmacology (Berl)       Date:  2002-03-23       Impact factor: 4.530

Review 5.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

6.  The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics?

Authors:  B Olivier; C Leahy; T Mullen; R Paylor; V E Groppi; Z Sarnyai; D Brunner
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

7.  Behavioral, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: comparisons with methamphetamine.

Authors:  J M Witkin; N Savtchenko; M Mashkovsky; M Beekman; P Munzar; M Gasior; S R Goldberg; J T Ungard; J Kim; T Shippenberg; V Chefer
Journal:  J Pharmacol Exp Ther       Date:  1999-03       Impact factor: 4.030

8.  Strain differences in the disruption of prepulse inhibition of startle after systemic and intra-accumbens amphetamine administration.

Authors:  Neal R Swerdlow; Jody M Shoemaker; Michele J Bongiovanni; Alaina C Neary; Laura S Tochen; Richard L Saint Marie
Journal:  Pharmacol Biochem Behav       Date:  2007-04-03       Impact factor: 3.533

Review 9.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

10.  Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine.

Authors:  M Weber; M Breier; D Ko; N Thangaraj; D E Marzan; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2008-12-09       Impact factor: 4.530

View more
  5 in total

1.  Effects of selective estrogen receptor alpha and beta modulators on prepulse inhibition in male mice.

Authors:  Marie A Labouesse; Wolfgang Langhans; Urs Meyer
Journal:  Psychopharmacology (Berl)       Date:  2015-04-18       Impact factor: 4.530

2.  Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine.

Authors:  J F C Pedrazzi; A C Issy; F V Gomes; F S Guimarães; E A Del-Bel
Journal:  Psychopharmacology (Berl)       Date:  2015-05-06       Impact factor: 4.530

3.  Examination of methylphenidate-mediated behavior regulation by glycogen synthase kinase-3 in mice.

Authors:  Marjelo A Mines; Eleonore Beurel; Richard S Jope
Journal:  Eur J Pharmacol       Date:  2012-10-23       Impact factor: 4.432

4.  Sensorimotor gating is disrupted by acute but not chronic systemic exposure to caffeine in mice.

Authors:  Sylvain Dubroqua; Benjamin K Yee; Philipp Singer
Journal:  Psychopharmacology (Berl)       Date:  2014-04-12       Impact factor: 4.530

5.  Activation of dopamine neurons is critical for aversive conditioning and prevention of generalized anxiety.

Authors:  Larry S Zweifel; Jonathan P Fadok; Emmanuela Argilli; Michael G Garelick; Graham L Jones; Tavis M K Dickerson; James M Allen; Sheri J Y Mizumori; Antonello Bonci; Richard D Palmiter
Journal:  Nat Neurosci       Date:  2011-04-17       Impact factor: 24.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.